Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 137-146

  Qin, Guo Qiang ^a,b   He, Hui Chan ^b   Han, Zhao Dong ^b   Liang, Yu Xiang ^b   Yang, Sheng Bang ^b   Huang, Ya Qiang ^b   Zhou, Liang ^b   Fu, Hao ^b   Li, Jie Xian ^a,b   Jiang, Fu Neng ^b   Zhong, Wei De ^b,c  

^a Panyu Central Hospital   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Biochemical recurrence free survival; Clinicopathological feature; HIVEP3; Prostate cancer; SOX9

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS TYPE I ENHANCER BINDING PROTEIN 3; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84893070359     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S55432     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Armstrong AJ, Eisenberger MA, Halabi S, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61(3):549-559.
3. Lumen N, Fonteyne V, De Meerleer G, et al. Screening and early diagnosis of prostate cancer: an update. Acta Clin Belg. 2012;67(4):270-275.
4. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer. 2000;88(Suppl 12):3009-3014.
5. Hu R, Denmeade SR, Luo J. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab. 2010;5(5):753-764.
6. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339(15):1036-1042.
7. Hicar MD, Robinson ML, Wu LC. Embryonic expression and regulation of the large zinc finger protein KRC. Genesis. 2002;33(1):8-20.
8. Allen CE, Mak CH, Wu LC. The kappa B transcriptional enhancer motif and signal sequences of V(D)J recombination are targets for the zinc finger protein HIVEP3/KRC: a site selection amplification binding study. BMC Immunol. 2002;3:10.
9. Oukka M, Wein MN, Glimcher LH. Schnurri-3 (KRC) interacts with c-Jun to regulate the IL-2 gene in T cells. J Exp Med. 2004; 199(1):15-24.
10. Wein MN, Jones DC, Shim JH, et al. Control of bone resorption in mice by Schnurri-3. Proc Natl Acad Sci U S A. 2012;109(21):8173-8178.
11. Allen CE, Wu LC. Downregulation of KRC induces proliferation, anchorage independence, and mitotic cell death in HeLa cells. Exp Cell Res. 2000;260(2):346-356.
12. Oukka M, Kim ST, Lugo G, Sun J, Wu LC, Glimcher LH. A mammalian homolog of Drosophila schnurri, KRC, regulates TNF receptor-driven responses and interacts with TRAF2. Mol Cell. 2002; 9(1):121-131.
13. Endo Y, Deonauth K, Prahalad P, Hoxter B, Zhu Y, Byers SW. Role of Sox-9, ER81 and VE-cadherin in retinoic acid-mediated trans-differentiation of breast cancer cells. PLoS One. 2008;3(7):e2714.
14. Schaeffer EM, Marchionni L, Huang Z, et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 2008;27(57):7180-7191.
15. Huang Z, Hurley PJ, Simons BW, et al, Schaeffer EM. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget. 2012;3(6):651-663.
16. Wang H, Leav I, Ibaragi S, et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 2008;68(6):1625-1630.
17. Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res. 2007;67(2):528-536.
18. Zhong WD, Qin GQ, Dai QS, et al. SOXs in human prostate cancer: implication as progression and prognosis factors. BMC Cancer. 2012;12:248.
19. Samant GV, Schupp MO, François M, et al. Sox factors transcriptionally regulate ROBO4 gene expression in developing vasculature in zebrafish. J Biol Chem. 2011;286(35):30740-30747.
20. Cui J, Shen X, Zhao H, Nagahama Y. Genome-wide analysis of Sox genes in Medaka (Oryzias latipes) and their expression pattern in embryonic development. Cytogenet Genome Res. 2011;134(4):283-294.
21. Gracz AD, Magness ST. Sry-box (Sox) transcription factors in gastrointestinal physiology and disease. Am J Physiol Gastrointest Liver Physiol. 2011;300(4):G503-G515.
22. Wei L, Cheng D, Li D, et al. Identification and characterization of Sox genes in the silkworm, Bombyx mori. Mol Biol Rep. 2011;38(5): 3573-3584.
23. Jakob S, Lovell-Badge R. Sex determination and the control of Sox9 expression in mammals. FEBS J. 2011;278(7):1002-1009.
24. Tsuchiya M, Ogawa H, Suzuki T, Sugiyama N, Haraguchi T, Hiraoka Y. Exportin 4 interacts with Sox9 through the HMG Box and inhibits the DNA binding of Sox9. PLoS One. 2011;6(10):e25694.
25. Sashikawa Kimura M, Mutoh H, Sugano K. SOX9 is expressed in normal stomach, intestinal metaplasia, and gastric carcinoma in humans. J Gastroenterol. 2011;46(11):1292-1299.
26. Drivdahl R, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Plymate SR. Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. Oncogene. 2004;23(26):4584-4593.
27. Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res. 2007;67(2):528-536.
28. Wang H, Leav I, Ibaragi S, et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 2008;68(6):1625-1630.
29. Thomsen MK, Ambroisine L, Wynn S, et al; Transatlantic Prostate Group. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 2010;70(3):979-987.
30. Huang Z, Hurley PJ, Simons BW, et al. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget. 2012;3(6):651-663.
31. Allen CE, Muthusamy N, Weisbrode SE, Hong JW, Wu LC. Developmental anomalies and neoplasia in animals and cells deficient in the large zinc finger protein KRC. Genes Chromosomes Cancer. 2002;35(4):287-298.